BMY
Bristol-Myers Squibb Company · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -4.8% ·
share flow -4.4% ·
net new positions -5.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 2.35M | $122.19M | n/a | −1 |
| Q2 2026 | 172 | +1 | 1.32B | $76.14B | +6 | −6 |
| Q1 2026 | 175 | +1 | 1.27B | $76.90B | +4 | −4 |
| Q4 2025 | 173 | +1 | 1.36B | $73.29B | +2 | n/a |
| Q3 2025 | 26 | 0 | 840.35M | $37.89B | n/a | −1 |
| Q2 2025 | 24 | +1 | 649.62M | $30.06B | +2 | −1 |
| Q1 2025 | 20 | 0 | 256.22M | $15.62B | +1 | −1 |
| Q4 2024 | 20 | -1 | 253.42M | $14.33B | n/a | −1 |
| Q3 2024 | 20 | +1 | 169.93M | $8.78B | +1 | n/a |
| Q2 2024 | 19 | n/a | 159.17M | $6.60B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 95.14M | n/a | $5.38B | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 44.39M | +2.8% | $2.51B | 0.2% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 35.18M | +2.3% | $1.99B | 0.3% | ▲ Add | 3 | SEC ↗ |
| 4 | PRIMECAP Management ✦ | 22.77M | -2.5% | $1.29B | 1.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Dodge & Cox ✦ | 15.40M | -1.4% | $871.16M | 0.5% | ▼ Trim | 3 | SEC ↗ |
| 6 | Millennium Management ✦ | 8.48M | +63.6% | $479.76M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 7.77M | +72.9% | $439.43M | 0.8% | ▲ Add | 3 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 7.53M | -62.8% | $425.78M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 9 | Wellington Management ✦ | 5.98M | +3880.0% | $338.09M | 0.1% | ▲ Add | 3 | SEC ↗ ×7 |
| 10 | AQR Capital Management ✦ | 4.01M | +2.7% | $226.62M | 0.3% | ▲ Add | 3 | SEC ↗ ×6 |
| 11 | Bridgewater Associates ✦ | 2.06M | +237.7% | $116.57M | 0.5% | ▲ Add | 3 | SEC ↗ |
| 12 | Point72 Asset Management ✦ | 1.41M | -51.0% | $79.77M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 1.35M | -13.2% | $76.49M | 0.1% | ▼ Trim | 3 | SEC ↗ ×2 |
| 14 | Renaissance Technologies ✦ | 1.06M | +16.7% | $59.98M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 275.54K | -18.2% | $15.58M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 16 | Fisher Asset Management ✦ | 223.88K | -1.1% | $12.66M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 158.46K | -92.2% | $8.96M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | GAMCO Investors ✦ | 104.58K | -5.7% | $5.92M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 85.62K | -98.2% | $4.84M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 41.54K | -99.2% | $454,236 | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $44.92M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 6.60K shares, $400 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 6.25K sh · $403,498
Officer · 500 sh · $33,750
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology